<img src="https://ml.globenewswire.com/Resource/Download/e18bf823-ff44-4bbd-82b9-3a311d58dad8?size=2" nborder="0" align="left" hspace="5" vspace="5" title="FINAL-logo-horizontal.png" alt="RenovoRx, Inc."/>PET-CT imaging, Rather than CT Alone, Presented a Meaningful Reduction in Tumor Metabolic Activity After Treatment, Suggesting that PET May Help to Optimize Therapeutic Response Monitoring Following Treatment Delivered via Trans-Arterial Micro-Perfusion (TAMP)MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports. The case study highlights potential optimization of the TAMP procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer (LAPC). Importantly, PET-CT imaging, rather than CT alone, showed a meaningful reduction in tumor metabolic activity after treatment, suggesting that PET may improve monitoring of therapeutic response following treatment delivered via TAMP. The case study, titled “Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch,” was authored by Bela Kis, MD, PhD, and his colleagues at Moffitt Cancer Center and published in Radiology Case Reports. This is the first reported case in which physicians successfully embolized, or sealed off, a small branching artery using tiny coils and surgical glue to better optimize isolation of flow with TAMP-mediated gemcitabine delivered with RenovoCath during the same procedure. The case study describes treatment of an 82-year-old patient with unresectable LAPC who underwent targeted intra-arterial gemcitabine treatment using TAMP following stereotactic body radiation therapy. During the procedure, physicians identified a pancreaticoduodenal artery (PDA) side branch that prevented optimal vessel isolation required for TAMP’s approach to pressure-mediated drug-delivery. Investigators subsequently performed coil plus glue embolization of the side branch, successfully enabling localized gemcitabine delivery via TAMP in the same procedural setting. The patient tolerated all 8 TAMP procedures (twice per month) without complications. Post eighth treatment at the 4-month follow-up, CT scans revealed stable disease (no change in tumor size) relative to scans performed prior to the first TAMP treatment, whereas PET-CT revealed a 52% reduction in tumor metabolic activity at the site of treatment. “LAPC is already difficult-to-treat, and a pancreaticoduodenal artery (PDA) side branch adds another challenge to targeted therapy,” said Bela Kis, MD, PhD, Moffitt Cancer Center and the first author of the case study. “TAMP uses RenovoCath, an innovative dual-balloon occlusion catheter designed to deliver therapy directly near tumors while reducing systemic exposure. The technology creates localized intra-arterial pressure that drives therapeutic agents across the vessel wall near the tumor.” Dr. Kis added, “We were encouraged by this case because the patient completed all eight RenovoCath-enabled TAMP treatments without complications. At the four-month follow-up, PET-CT imaging showed stable disease, while metabolic imaging indicated a positive treatment response, including a 52% reduction in fluorodeoxyglucose (FDG) activity at the treatment site.” “These findings further strengthen the growing body of peer-reviewed evidence supporting the procedural flexibility and targeted delivery capabilities of our TAMP therapy platform enabled by RenovoCath,” said Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder. “They also show how physicians may be able to address anatomical challenges to optimize targeted intra-arterial therapy, potentially increasing the therapeutic benefit of localized treatment options for patients with difficult-to-treat cancers.” Publication Details Title: Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch Journal: Radiology Case Reports DOI: <a href="https://www.globenewswire.com/Tracker?data=_IgD5JYoWWT2yG3aERKqUgBLUDBXjRF8i_xBQMAm6ad26LoO_WjiBDr58w2lt47yrpTii6urFQg51_GilleNgC0Zy1wjB98m2R0q5sTXroZzALp-3xAlUrS28K6aRqpG9UgJq9C0xb63E0kCS41u34USjOJ520swZ2ABtqXbAwE=" rel="nofollow" target="_blank" title="">https://doi.org/10.1016/j.radcr.2026.04.043</a> Lead Author: Dr. Bela Kis, MD, PhD Institution: Moffitt Cancer Center, Tampa, FL About RenovoCath Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: <a href="https://www.globenewswire.com/Tracker?data=kjWhuAj4L4E7BjpswaL3sLblvzzq-Qij6zN5uEPqQ7fhxoxJnRB8Y9CvGHQMyd0XtqBiI9fBii85ru6iqI_TUtw1sQ_GHKW1a9RO20jadOErsH2bczB34Ut8Ngpa0SHveUZQnOPfLJikWEKopYHpPeEMjI-0TGaRCEEuMvbKPd3yeSd0pZIxGPiIdJXPK_zJ" rel="nofollow" target="_blank" title="">IFU-10004-Rev.-G-Universal-IFU.pdf</a>. About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales and a record $563,000 of sales in the first quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers. RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx anticipates full enrollment in the TIGeR-PaC trial in June 2026 and final data readout in mid to late 2027. The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=2jp4VmZmq3oAD0kY2twBeIriAAsijm_GN5_NdP6V7c3t2vObtySKYQLY9HOXQxVV5aLgNkYehMuoG2ynsKGyyg3mrgIaPaNrYCTa1sa_ik8=" rel="nofollow" target="_blank" title="www.renovorx.com">www.renovorx.com</a>. Follow RenovoRx on <a href="https://www.globenewswire.com/Tracker?data=AEGqTHcb2oesWB7xanGkkaHe0tN_bdvlcM4uj_H4zjaMCJHc53BmS-z3QwWSEXk7aB66-WtL3yVWV3FHG4tU7gMed0V95UJVtD6Jsufysjc=" rel="nofollow" target="_blank" title="">Facebook</a>, <a href="https://www.globenewswire.com/Tracker?data=Mo0mdIYetbkUegpx0gLbzgJC69kovM3X9q6FWqNXJZgjkcCrOOY2DgjIIJZTFu-JHxkBM2mCKyvSEBmBlZOpbHYp8IN1N40frjA6UBHBkM0XEg7YIACR2Pdl-86KmlTR" rel="nofollow" target="_blank" title="">LinkedIn</a>, and <a href="https://www.globenewswire.com/Tracker?data=UIdTyamHOMOWv4ezUP044pvZYSV6-vx3uiLPdLoo0rV4dYG62cWdXd4dGZBwQ8kvAjn9Be3s26ps8sxdx98wFw==" rel="nofollow" target="_blank" title="">X</a>. Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies (including the anticipated benefits to the Company of the published case study described herein and potential positive implications for the TAMP therapy platform and RenovoCath), (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. These and other forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on such current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” "aim," "goal," “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. Risks, uncertainties and assumptions that could cause actual events to differ materially from those projected or indicated by forward-looking statements, include, without limitation: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xvii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at <a href="https://www.globenewswire.com/Tracker?data=_IgD5JYoWWT2yG3aERKqUlYkshluSDfr7y-Kgykvt_gHvNzw0Y_45Y-nJaUN4Gx65jMTU6JuqLKxo3lHBomp3dpfQVhs3eBIfvRKAF0CyAS7-aCmdGKJBvQjT7XBPVYqgAok2ZIJS2zQeIDB40Ku9w==" rel="nofollow" target="_blank" title="">https://ir.renovorx.com/sec-filings</a>. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investor Relations Contact: KCSA Strategic Communications Valter Pinto or Jack Perkins T: 212-896-1254 <a href="https://www.globenewswire.com/Tracker?data=hjloFRrOVmeuxMC8BoQGGkQWHHKd0prfcjcgg1Gif55xlUMVDZg__K6-H0QkIC1MwLK1UjI_d5O3zXsx5iP_yxXu86TK_2w3ONxFxDaowxQ=" rel="nofollow" target="_blank" title="RenovoRx@KCSA.com">RenovoRx@KCSA.com</a> Media Contact: STiR Communications Hannah Williams T: 803-521-1214 <a href="https://www.globenewswire.com/Tracker?data=Is8QoBn_5nTSr803Uj0ApHV7DpW8IZen-WooZo1XHtXp3uxC6kSFTvaZKQJbrdbRIcrG0-v9M5ZhI70gAiTT5tjKdNrodLk-jz_ihX9HbBToeEGBPPQxBVyWZng4kQvy" rel="nofollow" target="_blank" title="hannah@stir-communications.com">hannah@stir-communications.com</a> <img alt="" src='https://ml.globenewswire.com/media/NDM5YjQ4OGMtNjQ3Ni00MzEzLTk0ZjUtNmYzNWQ4MWQxZWEzLTEyMjA3MTAtMjAyNi0wNi0xMS1lbg==/tiny/RenovoRx-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn